CDDO Im

Biological Activity

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Nrf2 Suppresses Allergic Lung Inflammation by Attenuating the Type 2 Innate Lymphoid Cell Response
   R Nagashima, H Kosai, M Masuo, K Izumiyama, T Noshikawaj, M Morimoto, S Kumaki, Y Miyazaki, H Motohashi, M Yamamoto, N Tanaka
   J. Immunol., 2019;0(0):.
2. Macrophages Switch Their Phenotype by Regulating Maf Expression during Different Phases of Inflammation
   K Kikuchi, M Iida, N Ikeda, S Moriyama, M Hamada, S Takahashi, H Kitamura, T Watanabe, Y Hasegawa, K Hase, T Fukuhara, H Sato, EH Kobayashi, T Suzuki, M Yamamoto, M Tanaka, K Asano
   J. Immunol., 2018;0(0):.
3. CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes.
   Reisman et al.
   Toxicol.Appl.Pharmacol., 2009;236:109
4. 2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) directly targets mitochondrial glutathione to induce apoptosis in pancreatic cancer.
   Samudio et al.
   J.Biol.Chem., 2005;280:36273
5. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity.
   Aleksunes et al.
   J.Pharmacol.Exp.Ther., 2010;335:2

Product Datasheets